FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles

Novo,Nordisk,Advertising,Logo,On,Facade,Building,,Danish,Pharmaceutical,Healthcare

The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana.

In 2024, Novo Nordisk acquired three fill-finish sites from Novo Holdings A/S for $11 billion. The acquisition was part of a larger deal where Novo Holdings acquired Catalent, Inc. (NYSE:CTLT).